Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Experimentally-induced hyperuricaemia [due to inhibition of uricase with oxonic acid (OA)] in rats causes hypertension and renal alterations which can be prevented by lowering uric acid (UA) with allopurinol. Febuxostat (Fx), an investigational, nonpurine and selective xanthine oxidase inhibitor, is a more effective UA-lowering agent than allopurinol. We therefore tested the hypothesis that Fx might be useful in treating hyperuricemia-induced hypertension and renal damage. METHODS: Four groups of male rats were studied: OA (750 mg/kg by daily gavage) was given for 8 weeks and Fx (5-6 mg/kg/day in drinking water; OA+Fx: n = 10) or placebo (OA+P: n = 11) were administered for 4 weeks beginning at 4 weeks after initiation of the study. Two groups of normal (N) rats were studied as controls (N+P and N+Fx: n = 10/group). Systolic blood pressure (SBP) and fasting plasma UA were measured in all animals at baseline and at 4 and 8 weeks. Glomerular haemodynamics by micropuncture techniques were determined at 8 weeks followed by histological evaluation of glomerular and afferent arteriole morphologies. RESULTS: In OA-induced hyperuricaemic rats, Fx lowered UA and ameliorated systemic and glomerular hypertension as well as mesangial matrix expansion and the development of preglomerular arteriolar disease as indicated by a reduction of the arteriolar area and media-to-lumen ratio. In normal rats, Fx tended to lower UA and had no effect on blood pressure, renal hemodynamics and afferent arteriole morphology. CONCLUSION: These results suggest that Fx merits further evaluation for the treatment of hypertension and renal alterations induced by hyperuricaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout
Becker, M. A., Schumacher, H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., Streit, J., & Joseph-Ridge, N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050373 · Cited by 1,357
An Extremely Potent Inhibitor of Xanthine Oxidoreductase
Okamoto, K., Eger, B. T., Nishino, T., Kondo, S., Pai, E. F., & Nishino, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208307200 · Cited by 434
Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury
Simons, J. L., Provoost, A. P., Anderson, S., Rennke, H. G., Troy, J. L., & Brenner, B. M. (1994) · Kidney International · doi:10.1038/ki.1994.287 · Cited by 83 · cited 1×
“In addition, there is a correlation between glomerular pressure and arterial pressure, suggesting that in these rats the mechanism responsible for maintaining PGC is less effective, exposing glomerular capillaries directly to variations in systemic blood pressure [31].”
Cited by
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Self-citationSerum uric acid and the risk of cardiovascular and renal disease
Borghi, C., Rosei, E. A., Bardin, T., Dawson, J., Dominiczak, A., Kielstein, J. T., Manolis, A. J., Perez-Ruiz, F., & Mancia, G. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000701 · Cited by 463
Uric acid and cardiovascular disease: A clinical review
Saito, Y., Tanaka, A., Node, K., & Kobayashi, Y. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.12.013 · Cited by 374
Oxidative Stress and Hypertension: Current Concepts
Briones, A. M., & Touyz, R. M. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0100-z · Cited by 343
Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia
Sánchez-Lozada, L. G., Soto, V., Tapia, E., Avila-Casado, C., Sautin, Y. Y., Nakagawa, T., Franco, M., Rodríguez-Iturbe, B., & Johnson, R. J. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00104.2008 · Cited by 312
Self-citation
Metadata
- Authors
- Sanchez-Lozada, L. G., Tapia, E., Soto, V., Avila-Casado, C., Franco, M., Zhao, L., & Johnson, R. J.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-08
- Volume
- 23
- Issue
- 4
- Pages
- 1179-1185
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2125380545
- Cited by
- 122
- References
- 3
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. https://app.cochat.ai/papers/10.1093/ndt/gfm783
- The paper
- Sanchez-Lozada, L. G., Tapia, E., Soto, V., Avila-Casado, C., Franco, M., Zhao, L., & Johnson, R. J. (2007). Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfm783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.